Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative.
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Solidsoft Reply Successfully Integrates the Hellenic Medicines Verification System into the European Medicines Verification Platform18.3.2025 10:00:00 CET | Press release
In collaboration with the Hellenic Medicines Verification Organisation (HMVO), Solidsoft Reply, a Reply Group company specialising in Microsoft Azure cloud-based enterprise solutions, has successfully integrated Greece’s Hellenic Medicines Verification System (HMVS) within the European Hub, delivering the launch on schedule. This achievement enhances Greece’s pharmaceutical landscape and protects its citizens from the growing threat of falsified medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318137690/en/ The HMVS now operates as part of the European Medicines Verification System (EMVS), a pan-national platform designed to prevent counterfeit medicines from entering the market and reaching patients. With this launch, Greece joins a growing network of 15 other fully operational and secure National Medicine Verification System (NMVS) platforms across Europe, powered by Solidsoft Reply. The HMVS became fully ope
LUMENION sets new standards with CO2-free process steam for industrial applications18.3.2025 10:00:00 CET | Press release
"Green steam" supply with thermal storage in operation and available for all industrial sectors"Green Discount": solution supports decarbonization while enabling cost-efficient electrification of industrial processes LUMENION has successfully completed the test operation of a plant for the supply of "green steam" in combination with a large-scale thermal storage solution. The completion of this LUMENION solution marks an important milestone on the way to a decarbonized industry. The TÜV-certified system is available for applications in all industrial sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318462006/en/ LUMENION TES LUMENION's thermal energy storage system uses a few hours of electricity supply to charge and to store energy in the form of heat of up to 600° Celsius. The energy can be charged flexibly at intervals throughout the day and is made available to customers in the form of steam or process heat ove
Japan Sake and Shochu Makers Association: Global Beverage Experts Explore Japan’s Sake, Honkaku Shochu, and Awamori Culture18.3.2025 09:19:00 CET | Press release
The Japan Sake and Shochu Makers Association (JSS) is hosting a special tour inviting top professionals from the global wine and bar industries to explore the depth and heritage of Japan’s sake, honkaku shochu, and awamori culture. This exclusive program offers first-hand experience of Japan’s traditional brewing and distilling techniques, which were recently recognized as a UNESCO Intangible Cultural Heritage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316698311/en/ Leading Sommeliers Visiting a Rice Polishing Facility The sake tour brings together leading sommeliers and restaurant beverage directors from around the world to visit select breweries across Japan. Participants dive deep into the production process, learning about rice polishing, fermentation, and aging techniques unique to sake. The itinerary extends beyond brewery visits to an educational institute, offering specialized sessions on yeast selection, aro
Global Trust in Digital Services Declines, Finds Thales18.3.2025 09:00:00 CET | Press release
Thales 2025 Digital Trust Index reveals most industries experienced a decline in consumer trust compared to last year Privacy fears are becoming a major factor in consumer decisions to abandon brands. 82% doing so last year Banking tops the Trust Index for the second year in a row, but levels of trust fall to just 32% among Gen Z customers 33% of consumers voiced frustration with ecommerce, directly caused by bad bots manipulating the customer purchasing process Thales, today announced the findings of its 2025 Digital Trust Index – Consumer Edition, revealing a universal decline in trust for digital services compared to this time last year. Across 13 different sectors, only insurance, banking and Government saw either their trust level remain unchanged or increase very slightly. When asked which sector they trusted with their personal data, not one sector reached above 50% approval. Thales surveyed over 14,000 consumers across 14 countries about their online relationship with brands an
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support18.3.2025 09:00:00 CET | Press release
Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom